Evidence map›Paper›PMID 42904995›Full record

ArticleJournal of agricultural and food chemistry2026

PK/PD Modeling of a Novel Pleuromutilin Derivative Pleuro2-4 against Mycoplasma gallisepticum in Chicks.

Feifei Zhao, Yizhen Zhu, Tingting Zhang, Wei Wei, Honghao Huang, Dongping Zeng, Wenguang Xiong, Youzhi Tang, Zhenling Zeng

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of agricultural and food chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Feifei ZhaoGuangdong Provincial Key Laboratory of Veterinary Pharmaceutics Development and Safety Evaluation, College of Veterinary Medicine, South China Agricultural University, Guangzhou510642, China.
Yizhen ZhuGuangdong Provincial Key Laboratory of Veterinary Pharmaceutics Development and Safety Evaluation, College of Veterinary Medicine, South China Agricultural University, Guangzhou510642, China.
Tingting ZhangGuangdong Provincial Key Laboratory of Veterinary Pharmaceutics Development and Safety Evaluation, College of Veterinary Medicine, South China Agricultural University, Guangzhou510642, China.
Wei WeiGuangdong Provincial Key Laboratory of Veterinary Pharmaceutics Development and Safety Evaluation, College of Veterinary Medicine, South China Agricultural University, Guangzhou510642, China.
Honghao HuangGuangdong Provincial Key Laboratory of Veterinary Pharmaceutics Development and Safety Evaluation, College of Veterinary Medicine, South China Agricultural University, Guangzhou510642, China.
Dongping ZengGuangdong Provincial Key Laboratory of Veterinary Pharmaceutics Development and Safety Evaluation, College of Veterinary Medicine, South China Agricultural University, Guangzhou510642, China.ORCID 0000-0002-2006-5755
Wenguang XiongGuangdong Provincial Key Laboratory of Veterinary Pharmaceutics Development and Safety Evaluation, College of Veterinary Medicine, South China Agricultural University, Guangzhou510642, China.
Youzhi TangGuangdong Provincial Key Laboratory of Veterinary Pharmaceutics Development and Safety Evaluation, College of Veterinary Medicine, South China Agricultural University, Guangzhou510642, China.ORCID 0000-0003-2293-0287
Zhenling ZengGuangdong Provincial Key Laboratory of Veterinary Pharmaceutics Development and Safety Evaluation, College of Veterinary Medicine, South China Agricultural University, Guangzhou510642, China.ORCID 0000-0002-1103-7170

Funding

National Key Research and Development Program of China NA
6 · The paper itself

Abstract

Mycoplasma gallisepticum is a major causative agent of chronic respiratory disease in poultry, and effective antimicrobial therapy remains essential for disease control. In this study, the antimycoplasmal activity, pharmacokinetics, therapeutic efficacy, and pharmacokinetic/pharmacodynamic (PK/PD) model of Pleuro2-4, a novel pleuromutilin candidate, were systematically evaluated against M. gallisepticum. Pleuro2-4 exhibited potent in vitro activity (MIC = 0.0078 μg/mL) and concentration-dependent killing. Following oral administration in chicks, Pleuro2-4 was rapidly converted to its active metabolite and displayed rapid absorption and sustained exposure in lung tissue. In an M. gallisepticum infection model, Pleuro2-4 alleviated respiratory lesions, reduced mycoplasmal loads, and suppressed inflammatory responses. PK/PD integration using an inhibitory sigmoid Emax model identified AUC0-24h/MIC as the PK/PD index for dose optimization. The bactericidal target was 3372.82 h, corresponding to a recommended oral dosage of 44.99 mg/kg once daily for three consecutive days. These findings support Pleuro2-4 as a promising candidate for avian mycoplasmosis treatment.

Indexed as

Anti-Bacterial AgentsDiterpenesMycoplasma gallisepticumMycoplasma InfectionsPoultry DiseasesAnimalsChickensMicrobial Sensitivity TestsPleuromutilinsAnti-Bacterial AgentsDiterpenesPleuromutilinsdosage optimizationdrug developmentMycoplasma gallisepticumpharmacodynamicspharmacokineticspleuromutilin derivative

Identifiers

PMID42904995

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.